JP2015119705A5 - - Google Patents

Download PDF

Info

Publication number
JP2015119705A5
JP2015119705A5 JP2014263739A JP2014263739A JP2015119705A5 JP 2015119705 A5 JP2015119705 A5 JP 2015119705A5 JP 2014263739 A JP2014263739 A JP 2014263739A JP 2014263739 A JP2014263739 A JP 2014263739A JP 2015119705 A5 JP2015119705 A5 JP 2015119705A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
dual target
target antibody
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014263739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015119705A (ja
Filing date
Publication date
Priority claimed from KR1020090044032A external-priority patent/KR101224468B1/ko
Application filed filed Critical
Publication of JP2015119705A publication Critical patent/JP2015119705A/ja
Publication of JP2015119705A5 publication Critical patent/JP2015119705A5/ja
Pending legal-status Critical Current

Links

JP2014263739A 2009-05-20 2014-12-26 新規な形態の二重標的抗体およびその使用 Pending JP2015119705A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090044032A KR101224468B1 (ko) 2009-05-20 2009-05-20 신규한 형태의 이중표적항체 및 그 용도
KR10-2009-0044032 2009-05-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012511742A Division JP5744012B2 (ja) 2009-05-20 2009-07-22 新規な形態の二重標的抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2015119705A JP2015119705A (ja) 2015-07-02
JP2015119705A5 true JP2015119705A5 (cg-RX-API-DMAC7.html) 2015-11-12

Family

ID=43126324

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012511742A Expired - Fee Related JP5744012B2 (ja) 2009-05-20 2009-07-22 新規な形態の二重標的抗体およびその使用
JP2014263739A Pending JP2015119705A (ja) 2009-05-20 2014-12-26 新規な形態の二重標的抗体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012511742A Expired - Fee Related JP5744012B2 (ja) 2009-05-20 2009-07-22 新規な形態の二重標的抗体およびその使用

Country Status (13)

Country Link
US (1) US10125194B2 (cg-RX-API-DMAC7.html)
EP (1) EP2433968B1 (cg-RX-API-DMAC7.html)
JP (2) JP5744012B2 (cg-RX-API-DMAC7.html)
KR (1) KR101224468B1 (cg-RX-API-DMAC7.html)
CN (1) CN102428104B (cg-RX-API-DMAC7.html)
AU (1) AU2009346447B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0924535B1 (cg-RX-API-DMAC7.html)
CA (1) CA2762555C (cg-RX-API-DMAC7.html)
DK (1) DK2433968T3 (cg-RX-API-DMAC7.html)
ES (1) ES2605604T3 (cg-RX-API-DMAC7.html)
RU (1) RU2520824C2 (cg-RX-API-DMAC7.html)
SG (1) SG175971A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010134666A1 (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
WO2013076580A2 (en) 2011-11-23 2013-05-30 Bioven 3 Limited Recombinant proteins and their therapeutic uses
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
DK2924052T3 (da) * 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
KR102049991B1 (ko) 2013-03-28 2019-12-02 삼성전자주식회사 항 c-Met/항 Her2 이중 특이 항체
KR102074421B1 (ko) 2013-03-29 2020-02-10 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
DK2994485T3 (en) * 2013-05-06 2018-04-23 Sanofi Sa CONTINUOUS MULTIPLE STEP PROCEDURE FOR PURIFICATION OF ANTIBODIES
KR20150063728A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
AR100271A1 (es) 2014-05-19 2016-09-21 Lilly Co Eli Compuestos de vegfr2 / ang2
JP6768639B2 (ja) 2014-05-23 2020-10-21 セルデックス セラピューティクス,インコーポレーテッド 好酸球又はマスト細胞関連障害の治療
KR20160024639A (ko) 2014-08-26 2016-03-07 삼성전자주식회사 c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF
WO2016060297A1 (ko) * 2014-10-16 2016-04-21 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
FI3322727T3 (fi) 2015-07-15 2026-03-17 Genmab As Humanisoituja tai kimeerisiä CD3-vasta-aineita
BR112019000512A2 (pt) 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
CA3035723A1 (en) * 2016-09-08 2018-03-15 Woori Technologies Corporation Deglycosylated antibody specifically binding to clec14a and uses thereof
LT3592769T (lt) 2017-03-09 2024-08-26 Genmab A/S Antikūnai, atpažįstantys pd-l1
CN119285787A (zh) 2017-03-31 2025-01-10 健玛保控股有限公司 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
CN112055718A (zh) * 2018-03-19 2020-12-08 药物抗体公司 抗vegfr-2抗体
US11623960B2 (en) * 2018-03-20 2023-04-11 National Health Research Institutes Dual-function antibodies targeting VEGFR2 and VEGFR3
US11155575B2 (en) 2018-03-21 2021-10-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbent, devices and methods
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
AU2019354105A1 (en) 2018-10-04 2021-04-29 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-CD37 antibodies
CN113454111A (zh) 2018-11-06 2021-09-28 健玛保 抗体配制剂
WO2020159368A1 (en) 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
JP7447144B2 (ja) * 2019-08-14 2024-03-11 ファームアブシン・インコーポレイテッド 抗tie2抗体及びその用途
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
KR20220154757A (ko) 2020-03-18 2022-11-22 젠맵 에이/에스 B7h4에 결합하는 항체
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
WO2022029011A1 (en) 2020-08-06 2022-02-10 BioNTech SE Binding agents for coronavirus s protein
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
MX2023006832A (es) 2020-12-10 2023-08-22 Lava Therapeutics N V Anticuerpos que se unen a receptores de linfocitos t gamma-delta.
WO2022180271A1 (en) 2021-02-26 2022-09-01 LAVA Therapeutics N.V. Antibodies that bind CD123 and gamma-delta T cell receptors
KR20240004949A (ko) 2021-05-07 2024-01-11 젠맵 에이/에스 B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス, インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
KR20240055002A (ko) 2021-09-13 2024-04-26 얀센 바이오테크 인코포레이티드 암 치료를 위한 CD33 x Vδ2 다중특이성 항체
AR127298A1 (es) 2021-10-08 2024-01-10 Genmab As Anticuerpos que se unen a cd30 y cd3
JP2024538958A (ja) 2021-10-21 2024-10-28 ラヴァ・セラピューティクス・エヌ・ヴイ ガンマデルタt細胞活性化抗体の使用
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
NL2032398B1 (en) 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
TW202506178A (zh) 2023-04-05 2025-02-16 丹麥商珍美寶股份有限公司 包含與cd30和cd3結合之抗體之醫藥組成物
TW202509077A (zh) 2023-06-30 2025-03-01 丹麥商珍美寶股份有限公司 與纖維母細胞活化蛋白α及死亡受體4結合之抗體
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
TW202519261A (zh) 2023-07-27 2025-05-16 荷蘭商拉法醫療公司 用於治療癌症之結合γ-δ T細胞受體之抗體
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
CA2117893A1 (en) 1992-05-18 1993-11-25 Paul J. Godowski Variant dimers for receptor activation
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US7090843B1 (en) * 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
PT1916001E (pt) 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
AU2003224073C1 (en) * 2002-04-22 2010-03-11 AgroProtect GmbH Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
WO2004076485A1 (en) 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
WO2005024027A1 (ja) * 2003-09-02 2005-03-17 National Institute Of Advanced Industrial Science And Technology 抗体医薬
CN100503640C (zh) * 2004-07-08 2009-06-24 中国人民解放军军事医学科学院生物工程研究所 一种抗肿瘤融合蛋白及其编码基因与应用
WO2006005361A1 (en) * 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
CN1884300A (zh) * 2005-06-24 2006-12-27 中国人民解放军军事医学科学院微生物流行病研究所 一种具有靶向功能的抗肝癌超抗原,其制备方法及用途
WO2008090958A1 (ja) * 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물

Similar Documents

Publication Publication Date Title
RU2011146088A (ru) Антитело двойной направленности в новой форме и его применение
Bokhari et al. Vascular endothelial growth factor-D (VEGF-D): an angiogenesis bypass in malignant tumors
RU2509085C2 (ru) Стабилизированные антитела против ангиопоэтина-2 и их применение
FI3345613T3 (fi) Koostumus käytettäväksi syövän tai angiogeneesiin liittyvän sairauden hoidossa käsittäen tuumoriin penetroituvan peptidin ja VEGF-estäjän fuusioproteiinin
EA202092735A1 (ru) Антагонизирующее cd73 антитело
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
JP2011510632A5 (cg-RX-API-DMAC7.html)
EA201300311A1 (ru) Vegf-связывающие молекулы
CL2014000181A1 (es) Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11).
EA201591515A1 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
UA118096C2 (uk) ВИДІЛЕНА БІСПЕЦИФІЧНА МОЛЕКУЛА, ЩО ЗВ'ЯЗУЄТЬСЯ З ДОМЕНОМ ФІБРОНЕКТИНУ ІІІ ТИПУ EGFR I c-Met
IL256871B2 (en) Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof
EA201691304A1 (ru) АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA200970700A1 (ru) Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
EA201791366A1 (ru) Антитела к c5 и способы их применения
He et al. A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging
PE20080352A1 (es) COMPOSICIONES QUE COMPRENDEN ANTICUERPOS DE c-Met
EA201390738A1 (ru) Нейтрализующие антитела против ccl20
FI3722310T3 (fi) Vegf:ää estäviä stabiileja ja liukoisia vasta-aineita
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
EA201300470A1 (ru) Антитела